Androsin alleviates non-alcoholic fatty liver disease by activating autophagy and attenuating de novo lipogenesis
- 1 May 2024
- journal article
- research article
- Published by Elsevier in Phytomedicine
- Vol. 129, 155702
Abstract
No abstract availableKeywords
Funding Information
- Indian Council of Medical Research
This publication has 33 references indexed in Scilit:
- Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysisJournal of Clinical and Experimental Hepatology, 2022
- Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitorsEuropean Journal of Medicinal Chemistry, 2020
- Piceatannol attenuates fat accumulation and oxidative stress in steatosis-induced HepG2 cellsCurrent Research in Food Science, 2020
- Dietary Fat, but Not Protein or Carbohydrate, Regulates Energy Intake and Causes Adiposity in MiceCell Metabolism, 2018
- Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver DiseaseDigestive Diseases and Sciences, 2016
- Comparative pharmacokinetic profiles of picrosides I and II from kutkin, Picrorhiza kurroa extract and its formulation in ratsFitoterapia, 2013
- The Scap/SREBP Pathway Is Essential for Developing Diabetic Fatty Liver and Carbohydrate-Induced Hypertriglyceridemia in AnimalsCell Metabolism, 2012
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell GrowthCell Metabolism, 2008
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005